SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq: AFFX) announced today that the Children’s Hospital of Philadelphia will use the Affymetrix Genome-Wide Human SNP Array 6.0 for a series of whole-genome association studies. Researchers at the Children’s Hospital are extending their collaborations to investigators who have preference for the Affymetrix genotyping platform to identify the genes responsible for complex medical disorders, such as cardiovascular, metabolic and central nervous system (CNS) disorders. The results of these studies will enable scientists from around the world to develop more effective, personalized treatments.
